Summit Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -37 | -25 | -14,940 | -19 |
EBITDA | -565,671 | -62,888 | -61,145 | -53,515 |
EBIT | -565,708 | -62,913 | -61,078 | -53,535 |
Net Income | -565,708 | -62,913 | -61,203 | -56,254 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -66,744 | -61,590 | -48,687 | -30,355 |
Cash | 297,872 | 211,526 | 104,862 | 93,775 |
Basic Shares | 742,615 | 738,076 | 737,500 | 726,656 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $704 | $1,809 |
Gross Profit | -15,007 | -2,050 | -1,810 | 1,809 |
EBITDA | -212,853 | 1,001 | -73,118 | -83,731 |
EBIT | -230,001 | 845 | -74,381 | -86,186 |
Net Income | -221,315 | -614,928 | -78,782 | -86,147 |
Net Change In Cash | 0 | 0 | 704 | 1,809 |
Free Cash Flow | -142,245 | -76,888 | -42,206 | -72,893 |
Cash | 104,862 | 71,425 | 348,607 | 71,791 |
Basic Shares | 718,542 | 619,646 | 193,336 | 92,239 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.12 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.07 |
2024-09-30 | -$0.08 |
